Moderna Turns To Q3 Profit, Revenue Rises 29%; Raises Annual Revenue Growth Outlook
Moderna reported Q3 profit of $162M ($0.38 EPS) vs. last year's loss, with revenue up 29% to $1.31B. U.S. revenue was $780M, international $533M. The company raised its 2026 revenue growth outlook to 15-25% and lowered R&D expense forecast to $2.7B. Shares were down 1% premarket.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance provide fresh data for traders; however, the market's immediate reaction is a slight dip, indicating mixed sentiment.
Market read
First‑report earnings and guidance update for a mid‑cap biotech, offering actionable insight for short‑term traders.
What to watch
Potential headwinds from waning pandemic demand and competition from next‑gen mRNA platforms could limit upside.
Background
Moderna's Q3 results mark a return to profitability after a loss year earlier, driven by higher international COVID‑19 vaccine sales and lower R&D spend.
Ticker impact
Moderna reported Q3 profit, 29% revenue rise and raised full-year revenue growth outlook to 15-25%.
modest downside pressure as the market prices in the guidance lift after a 1% pre‑market decline
The surprise profit and higher guidance are new material, but the stock already fell ~1% pre‑market, suggesting limited upside.
Market effects
Biotech sector may see modest uplift as a major mRNA player posts profit and raises guidance.
US biotech stocks could experience slight positive bias in early trading.
Limited; impact confined to vaccine‑related biotech investors.
Counterpoint
Despite the profit beat, the modest pre‑market decline suggests investors remain cautious about future demand for COVID‑19 vaccines.
Key entities
- CompanyModerna, Inc.
Biotech firm developing mRNA vaccines and therapeutics.
